Ignite Creation Date:
2024-05-06 @ 12:25 PM
Last Modification Date:
2024-10-26 @ 12:58 PM
Study NCT ID:
NCT03751761
Status:
COMPLETED
Last Update Posted:
2024-02-28
First Post:
2018-11-21
Brief Title:
GC 2nd Line DurvalumabMEDI4736Tremelimumab Plus Paclitaxel Study
Sponsor:
Asan Medical Center
Organization:
Asan Medical Center
Study Overview
Official Title:
DurvalumabMEDI4736Tremelimumab Plus Paclitaxel in Patients With Metastatic Gastric Cancer After Failure of First-line Chemotherapy Phase IbII
Status:
COMPLETED
Status Verified Date:
2024-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To evaluate safety and response rate of durvalumabtremelimumab in combination with paclitaxel in patients with metastatic gastric cancers who fail a first-line chemotherapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None